Top 20 Commercial Due Diligence (CDD) Advisory 2026

This report forms part of the Ranking News Advisory series, which evaluates specialized advisory firms across global strategy, transaction, and corporate advisory markets.

Commercial Due Diligence (CDD) advisory firms play a critical role in transaction processes by evaluating the commercial viability of investment opportunities. Their work focuses on assessing market dynamics, growth potential, competitive positioning, customer behavior, and revenue sustainability, providing investors with forward-looking insight into whether a target business can deliver its projected performance.

Unlike financial due diligence, which validates historical financial information, commercial due diligence is inherently forward-looking and closely tied to investment thesis development. As a result, CDD providers are deeply embedded within private equity deal processes, often operating under tight timelines and directly influencing investment decisions.

The market is characterized by a mix of specialized strategy boutiques and sector-focused advisory firms, many of which maintain strong relationships with private equity sponsors. These firms differentiate themselves through analytical rigor, speed of execution, and deep industry expertise.

This ranking identifies firms that demonstrate consistent engagement in commercial due diligence and transaction-related strategy advisory across global markets.

Market Overview

The commercial due diligence market has expanded significantly alongside the growth of private equity activity. As competition for assets has intensified, investors have placed greater emphasis on validating market assumptions, understanding demand drivers, and identifying downside risks prior to acquisition.

CDD providers typically operate at the intersection of strategy consulting and transaction advisory. Their role is to translate complex market data into clear investment recommendations within compressed timelines. This requires both analytical capability and sector familiarity.

Mid-market private equity transactions represent a significant portion of demand, where investors seek advisors capable of delivering focused and actionable insights. In this segment, boutique firms often compete effectively against larger consulting platforms by offering greater flexibility and senior-level involvement.

Sector specialization has become increasingly important. Firms with deep expertise in areas such as healthcare, technology, consumer, and industrial markets are better positioned to deliver high-quality analysis and secure repeat engagements.

Industry Trend — 2026

In 2026, commercial due diligence continues to evolve toward greater analytical depth and sector specialization. Private equity firms are increasingly demanding more granular insights into customer segmentation, pricing power, and competitive positioning.

Data availability has significantly expanded, allowing CDD providers to incorporate alternative data sources, customer-level analysis, and real-time market indicators into their assessments. This has improved the precision of market sizing and growth projections.

Another key trend is the integration of CDD with post-deal value creation planning. Investors are no longer satisfied with standalone diligence reports—they expect actionable recommendations that can be implemented immediately following acquisition.

Sector specialization is also becoming more pronounced. Firms with deep expertise in healthcare, software, industrials, and consumer sectors are better positioned to secure repeat mandates from private equity sponsors.

Speed remains a defining characteristic of the category. Firms that can deliver high-quality insights within tight timelines continue to dominate competitive deal environments.

Methodology — Core Eligibility Criteria

To ensure structural consistency within the category, firms were evaluated based on the following criteria:

• Provides commercial due diligence services for transactions
• Demonstrates strong private equity engagement
• Focuses on market, growth, and competitive analysis
• Maintains dedicated transaction or diligence teams
• Exhibits sector specialization and analytical rigor

Large multi-service consulting platforms without a clear CDD-focused positioning were excluded.

Methodology — Ranking Factors

Firms included in the ranking were evaluated using a combination of qualitative and structural considerations. Key factors include:

• Depth of commercial analysis and market insight
• Strength of private equity relationships
• Ability to deliver clear investment recommendations
• Speed and reliability under transaction timelines
• Sector expertise and domain specialization
• Quality of data and analytical frameworks
• Institutional reputation in deal environments

The objective of the ranking is to identify firms whose advisory platforms maintain sustained relevance within the global corporate governance ecosystem.

The ranking universe consisted of approximately 55 Commercial Due Diligence (CDD) Advisory Firms, from which 20 institutions were selected for inclusion.

Tier classifications reflect relative institutional positioning and do not represent performance rankings or recommendations.

---

Tier I — Leading CDD Advisory Firms

Bain & Company — Private Equity Due Diligence

• Headquarters: Boston, United States
• Founded: 1973

Bain & Company is one of the most influential global strategy consulting firms in private equity due diligence, with a long-standing reputation for supporting sponsors across deal screening, commercial due diligence, investment thesis validation, sector strategy, and post-acquisition value creation. The firm’s private equity practice is deeply embedded in the global buyout ecosystem and is frequently involved in competitive, time-sensitive investment processes where sponsors must build conviction quickly.

Its CDD work focuses on market attractiveness, competitive positioning, customer behavior, growth potential, revenue sustainability, pricing dynamics, channel structure, and value creation opportunities. Bain’s ability to connect diligence findings with ownership plans gives it particular strength in sponsor-backed transactions where underwriting and post-close execution are closely linked.

Bain’s relevance also extends across software, technology, healthcare, consumer, industrials, financial services, and other sectors where investors need both market evidence and strategic interpretation. The firm is especially useful where commercial diligence must test not only whether a business is attractive today, but whether its market position can withstand competitive disruption, pricing pressure, customer churn, or technology change.

Bain belongs in Tier I because of its scale, private equity relationships, analytical discipline, sector depth, and reputation in diligence-led strategy work. Although broader than a CDD-only boutique, its private equity due diligence capability is one of the defining platforms in the market.

EY-Parthenon

• Headquarters: Boston, United States / London, United Kingdom
• Founded: 1991 Parthenon legacy; 2014 EY-Parthenon platform

EY-Parthenon is a major strategy and transactions advisory platform with strong capabilities in commercial due diligence, growth strategy, corporate strategy, and private equity advisory. The firm supports private equity investors, corporate acquirers, boards, and management teams across buy-side diligence, sell-side diligence, market assessment, investment thesis development, portfolio strategy, and value creation planning.

Its advantage comes from combining strategy consulting with EY’s wider transaction, financial, tax, valuation, operational, technology, cyber, sustainability, and risk advisory infrastructure. This makes EY-Parthenon especially relevant in transactions where commercial due diligence must be coordinated with broader deal execution, post-close planning, and cross-functional assessment.

EY-Parthenon’s commercial diligence work is particularly useful where investors need to understand market size, competitive dynamics, customer demand, pricing power, product differentiation, technology exposure, and future value creation potential. Its sector coverage allows it to support both large-cap and middle-market transactions across software, healthcare, industrials, consumer, education, financial services, and infrastructure-related markets.

EY-Parthenon belongs in Tier I because it combines global scale with a dedicated commercial diligence and strategy advisory identity. It is broader than a specialist boutique, but its CDD capability is sufficiently central to its private equity and transaction proposition to justify top-tier placement.

L.E.K. Consulting

• Headquarters: London, United Kingdom / Boston, United States
• Founded: 1983

L.E.K. Consulting is one of the most established commercial due diligence providers globally, with a strong presence across private equity, corporate strategy, transaction advisory, and growth strategy. The firm has built a reputation for rigorous, fact-based analysis under compressed deal timelines, making it a frequent participant in high-stakes investment processes.

Its CDD work focuses on market sizing, growth forecasting, customer segmentation, competitive positioning, pricing, channel dynamics, revenue sustainability, and investment thesis validation. L.E.K. has particular strength in healthcare, life sciences, consumer, industrials, education, technology, and business services, where granular market understanding is essential.

The firm’s model is especially relevant where investors require a structured view of the target’s addressable market, defensible growth trajectory, customer concentration, competitive threats, and post-acquisition strategic options. L.E.K.’s sector depth allows it to move beyond general market commentary and provide evidence-based diligence that can directly inform investment committee decisions.

L.E.K. belongs in Tier I because commercial due diligence is deeply embedded in its advisory identity. Its combination of analytical rigor, sector depth, private equity relationships, and transaction focus makes it one of the clearest benchmark firms in the CDD market.

OC&C Strategy Consultants

• Headquarters: London, United Kingdom
• Founded: 1987

OC&C Strategy Consultants is a strategy consulting boutique with a strong reputation in commercial due diligence, private equity advisory, corporate strategy, and growth strategy. The firm is especially recognized in consumer, retail, leisure, media, technology, business services, and related sectors where demand analysis, customer behavior, brand positioning, and market structure are central to transaction decisions.

Its CDD approach emphasizes evidence-based market assessment, customer behavior analysis, competitive benchmarking, pricing structures, category dynamics, channel economics, and revenue sustainability. OC&C’s focused sector model allows it to provide grounded insights that are directly relevant to investment committees, corporate acquirers, and management teams.

OC&C is particularly strong where the central diligence question is commercial rather than purely financial or operational: whether demand is resilient, whether the target has a differentiated market position, whether customer growth is achievable, and whether the investment thesis is supported by market evidence. Its boutique strategy identity gives it a distinct profile compared with broader transaction services platforms.

OC&C belongs in Tier I because it is one of the most credible independent strategy boutiques in the CDD space. Its focused advisory model, private equity relationships, sector concentration, and long-standing transaction support capability make it a strong top-tier inclusion.

Simon-Kucher

• Headquarters: Bonn, Germany
• Founded: 1985

Simon-Kucher is a global strategy consulting firm specializing in pricing, revenue growth, monetization, and commercial strategy, with an increasingly important role in transaction services and commercial due diligence. The firm supports private equity sponsors, strategic investors, and portfolio companies in assessing revenue quality, pricing power, market segmentation, customer willingness to pay, and value creation potential.

Its CDD work is especially relevant where growth assumptions depend on pricing, monetization strategy, customer behavior, sales effectiveness, channel performance, or commercial model resilience. Simon-Kucher provides a differentiated perspective compared with broader strategy firms because its diligence analysis often goes deeper into revenue mechanics, pricing strategy, margin expansion, and commercial execution.

The firm is particularly useful in software, healthcare, consumer, industrials, financial services, and technology-enabled markets where pricing architecture and revenue model design can materially affect investment outcomes. Its transaction services work can help investors test whether a target’s growth plan is credible, whether pricing upside exists, and whether commercial improvement opportunities are achievable after acquisition.

Simon-Kucher belongs in Tier I because it brings a distinctive commercial lens to due diligence. Its global scale, pricing expertise, transaction services practice, and revenue-growth orientation make it a strong CDD advisor, particularly for deals where revenue expansion and margin improvement are central to the investment thesis.

---

Tier II — Established CDD Advisory Firms

(Alphabetical order)

Altman Solon

• Headquarters: Boston, United States
• Founded: 2020 current platform; legacy firms earlier

Altman Solon is a specialized strategy consulting firm focused on telecommunications, media, technology, digital infrastructure, and related sectors. The firm has a strong role in commercial due diligence for transactions involving digital platforms, software, data-driven business models, media assets, telecom infrastructure, connectivity, and technology-enabled services.

Its advisory work combines sector knowledge with detailed market analysis, customer assessment, revenue forecasting, competitive positioning, and transaction strategy. Altman Solon is particularly relevant for private equity investors evaluating fast-moving TMT assets where technical market structure and commercial demand require specialized interpretation.

The firm is especially useful where investors need to understand subscriber economics, infrastructure demand, software adoption, media consumption trends, telecom regulation, digital transformation, or technology-led disruption. Its sector concentration allows it to produce sharper diligence outputs than generalist firms in markets where industry-specific assumptions can determine valuation and investment risk.

Altman Solon belongs in Tier II because it is narrower than the broad Tier I CDD platforms, but very strong within its core sectors. It should be positioned as a leading sector-specialist CDD advisor rather than a generalist diligence firm.

CIL

• Headquarters: London, United Kingdom
• Founded: 1986

CIL is a growth strategy and commercial due diligence consultancy serving private equity investors, corporate clients, and management teams. The firm supports clients across the deal lifecycle, including investment screening, commercial due diligence, growth strategy, exit planning, pricing, data strategy, and value creation.

Its CDD work is particularly relevant in mid-market and growth-oriented transactions where investors need a clear view of market attractiveness, competitive position, customer demand, and achievable growth. CIL’s sector coverage spans business services, healthcare, technology, education, consumer, industrials, infrastructure, and related markets.

The firm is especially useful where investors need diligence that connects market evidence with a practical value creation agenda. CIL’s work often helps sponsors and management teams clarify the target’s growth story, test market assumptions, identify customer and channel opportunities, and prepare a defensible commercial narrative for investment or exit.

CIL belongs in Tier II because it is highly aligned with commercial due diligence and private equity advisory while remaining more boutique and specialist than the Tier I global platforms. It is one of the clearest established CDD firms for a ranking focused on transaction-facing commercial diligence.

ClearView Healthcare Partners

• Headquarters: Boston, United States
• Founded: 2007

ClearView Healthcare Partners is a strategy consulting firm focused on life sciences and healthcare, with strong relevance in commercial due diligence for pharmaceutical, biotechnology, medical device, diagnostics, healthcare services, and life sciences tools assets. The firm supports corporate clients and investors in evaluating market opportunity, product positioning, competitive dynamics, clinical adoption, and growth potential.

Its CDD work is particularly valuable in highly regulated and scientifically complex markets where investment decisions require both technical understanding and commercial judgment. ClearView’s therapeutic-area expertise enables it to assess demand drivers, clinical workflows, reimbursement factors, competitive landscapes, commercialization pathways, and market access challenges.

The firm is especially relevant for healthcare investors and strategic acquirers evaluating assets where scientific novelty, regulatory timing, physician adoption, payer behavior, and competitive differentiation all influence commercial potential. Its specialist life sciences focus gives it a deeper diligence profile than generalist CDD firms in healthcare-intensive transactions.

ClearView belongs in Tier II because it is a leading healthcare specialist rather than a broad CDD platform. Its inclusion strengthens the ranking’s life sciences coverage while preserving a disciplined distinction between generalist diligence platforms and sector-specialist advisors.

DeciBio Consulting

• Headquarters: Los Angeles, United States
• Founded: 2009

DeciBio Consulting is a specialist strategy and market intelligence firm focused on precision medicine, diagnostics, research tools, life sciences, and healthcare technology. The firm provides commercial due diligence, market assessment, technology evaluation, voice-of-customer research, competitive analysis, and growth strategy support.

Its CDD work is especially relevant for investors evaluating complex healthcare assets where scientific novelty, regulatory pathways, reimbursement conditions, customer adoption, and technology differentiation all influence market potential. DeciBio’s sector focus allows it to provide deeper analysis than generalist diligence providers in diagnostics, precision medicine, life sciences tools, and emerging healthcare technology.

The firm is particularly useful where diligence depends on understanding specialist customer groups, laboratory workflows, clinical use cases, product-market fit, and future adoption curves. In markets where technical features and commercial opportunity are tightly linked, DeciBio can translate scientific and market evidence into investment-relevant judgment.

DeciBio belongs in Tier II because it is active, specialist, and directly aligned with healthcare and life sciences commercial diligence. It should be framed as a niche healthcare and precision-medicine CDD advisor rather than a full-spectrum commercial diligence firm.

GCS Insight

• Headquarters: London, United Kingdom
• Founded: 2017 GRAPH Strategy UK lineage; GCS Insight current brand

GCS Insight is a specialist strategy consulting firm providing commercial due diligence, customer value creation, strategic growth, and M&A strategy support. The firm was previously known as GRAPH Strategy UK before rebranding, and it continues to operate in the specialist diligence and growth advisory market.

Its work is particularly relevant in software, technology, data services, business services, education, infrastructure, and other sectors where customer economics, market growth, competitive differentiation, and recurring revenue quality are central to investment decisions. GCS’s evidence-led approach supports both pre-deal diligence and post-investment growth planning.

The firm is especially useful where investors need to test the commercial story behind a target: the size and resilience of the market, the quality of customer demand, the strength of the target’s value proposition, and the achievability of growth initiatives after investment. Its current branding gives the ranking exposure to a newer-generation boutique diligence platform with a clear CDD identity.

GCS Insight belongs in Tier II because it is a focused CDD and growth strategy specialist with a clear operating footprint. It adds a specialist UK-based advisory platform that is more directly aligned with commercial diligence than many broader management consulting firms.

Health Advances

• Headquarters: Boston, United States
• Founded: 1992

Health Advances is a healthcare and life sciences consulting firm with a strong commercial diligence capability. The firm supports investors, pharmaceutical companies, medical technology firms, diagnostics companies, healthcare organizations, and life sciences businesses in evaluating market opportunities, competitive dynamics, growth potential, and commercialization strategies.

Its CDD work is particularly relevant in healthcare transactions where clinical evidence, market access, reimbursement, product adoption, and stakeholder behavior must be assessed alongside market size and revenue forecasts. Health Advances brings deep domain expertise across biopharma, medtech, diagnostics, healthcare IT, healthcare services, and life sciences tools.

The firm is especially useful where investors require sector-specific judgment rather than generic market analysis. Healthcare diligence often requires understanding physicians, patients, payers, hospitals, laboratories, regulators, and channel partners simultaneously, and Health Advances is well positioned to interpret these stakeholder dynamics.

Health Advances belongs in Tier II because it is one of the more established healthcare-focused diligence advisors. It is not a generalist CDD firm, but its sector depth makes it highly credible in healthcare and life sciences transaction advisory.

Kearney — Private Equity Due Diligence

• Headquarters: Chicago, United States
• Founded: 1926

Kearney provides private equity and due diligence advisory services across commercial, operational, IT, digital, ESG, vendor, and carve-out diligence workstreams. The firm supports private equity investors and strategic acquirers in assessing markets, target business models, competitive positioning, scalability, operational performance, and value creation opportunities.

Its CDD relevance comes from its ability to combine commercial market analysis with operational and transformation expertise. This makes Kearney particularly useful in transactions where the investment thesis depends not only on market growth, but also on operational improvement, supply chain performance, procurement opportunity, cost structure, digital transformation, or organizational scalability.

Kearney is especially relevant in industrials, automotive, infrastructure, consumer, energy, technology, transportation, and manufacturing-related transactions where market structure and operational competitiveness must be assessed together. Its broad consulting capabilities allow it to connect pre-acquisition diligence with post-close value creation planning.

Kearney belongs in Tier II because it is a major global consulting firm with clear diligence capabilities, but CDD is one part of its broader advisory platform. It should be included for institutional breadth and transaction capability while leaving Tier I to firms with stronger CDD-specific market identity.

Oliver Wyman — Private Equity & Principal Investors

• Headquarters: New York, United States
• Founded: 1984

Oliver Wyman provides buy-side due diligence and private equity advisory services across sectors including financial services, transportation, healthcare, energy, industrials, technology, aviation, mobility, consumer markets, and infrastructure-related industries. The firm supports investors in assessing value proposition, market size, growth trajectory, competitive position, customer demand, and post-acquisition opportunities.

Its commercial diligence work is especially relevant in industries where regulation, risk, pricing, operational complexity, and sector structure shape market attractiveness. Oliver Wyman’s sector depth in financial services, insurance, mobility, aviation, transportation, and infrastructure gives it differentiated diligence capability in markets where generalist CDD analysis may be insufficient.

The firm is particularly useful where diligence must connect strategy, market structure, operational feasibility, and risk analysis. Its broader advisory platform allows investors to evaluate not only whether a market is attractive, but whether the target’s capabilities, economics, and strategic position are resilient under different industry scenarios.

Oliver Wyman belongs in Tier II because it is a strong global advisory platform with relevant CDD capabilities, but it is broader than a dedicated CDD boutique. Its inclusion adds institutional weight and sector diversity to the ranking.

Roland Berger

• Headquarters: Munich, Germany
• Founded: 1967

Roland Berger is a global strategy consulting firm with a strong European heritage and established private equity advisory capabilities. The firm supports strategic investors and private equity clients across commercial due diligence, operational due diligence, market assessment, portfolio strategy, value creation, and transformation planning.

Its CDD work is particularly relevant in industrials, automotive, infrastructure, technology, energy, consumer, manufacturing, and European mid-market transactions. Roland Berger’s sector expertise and European transaction footprint make it a strong advisor where market structure, industrial economics, operational competitiveness, and regional dynamics must be assessed together.

The firm is especially useful where investors require a combination of commercial assessment and strategic implementation perspective. Roland Berger’s work can help clients evaluate market attractiveness, competitive position, growth assumptions, operational constraints, and post-acquisition improvement potential in the same transaction context.

Roland Berger belongs in Tier II because it is active and credible in due diligence, while remaining broader than a CDD-only specialist. It strengthens the ranking’s European institutional coverage and balances the list beyond U.S. and UK firms.

Strategy& — Deals Strategy / Commercial Due Diligence

• Headquarters: New York, United States / London, United Kingdom
• Founded: 1914 Booz & Company heritage; 2014 Strategy& brand

Strategy& is PwC’s strategy consulting business and provides commercial due diligence, operational due diligence, value creation strategy, equity story development, and deal-related strategic advisory. The firm supports private equity investors and corporate clients through PwC’s broader deals and transaction infrastructure.

Its CDD work is particularly relevant where commercial market assessment must connect to financial, tax, operational, technology, and post-merger integration workstreams. Strategy& can combine strategy consulting with PwC’s wider transaction capabilities, making it useful in complex or multi-workstream deal processes.

The firm is especially appropriate for transactions where investors require both commercial insight and integrated deal execution support. Its work can help test market attractiveness, customer demand, competitive dynamics, growth potential, synergy logic, and post-acquisition value creation opportunities within a broader transaction framework.

Strategy& belongs in Tier II because it is a major strategy platform with explicit CDD capability, but its identity is broader and more integrated with PwC than the specialist Tier I CDD boutiques. It should be included for institutional breadth, sector depth, and transaction relevance.

---

Tier III — Specialist CDD Advisory Firms

(Alphabetical order)

Back Bay Life Science Advisors

• Headquarters: Boston, United States
• Founded: 2007

Back Bay Life Science Advisors is a specialized life sciences advisory firm combining strategy consulting and investment banking capabilities. The firm advises biotechnology, pharmaceutical, medical device, diagnostics, and healthcare technology companies and investors on commercialization, licensing, M&A, financing, product strategy, portfolio prioritization, valuation, and due diligence.

Its CDD relevance comes from its ability to assess market opportunity, product positioning, clinical and commercial pathways, partner interest, competitive dynamics, and transaction feasibility in highly specialized healthcare markets. This makes it useful for investors evaluating early-stage, growth-stage, or specialist healthcare assets where scientific and commercial interpretation must be joined.

Back Bay is especially relevant where the target’s value depends on technology adoption, clinical evidence, product-market fit, regulatory pathway, reimbursement potential, and strategic partnership opportunity. Its combined strategy and transaction perspective gives it a different profile from pure consulting firms or pure investment banks.

Back Bay belongs in Tier III because it is highly relevant in life sciences, but its model is broader than CDD alone and overlaps with investment banking. It is best positioned as a specialist healthcare transaction advisor with commercial diligence capability.

Baker Tilly — Commercial Due Diligence

• Headquarters: Chicago, United States / London, United Kingdom
• Founded: 1988 network formation; legacy firms earlier

Baker Tilly provides commercial due diligence services through dedicated strategy consultants supporting private equity firms, investors, corporates, and transaction stakeholders. Its CDD work focuses on market attractiveness, competitive positioning, customer demand, revenue growth, transaction-related commercial risk, and independent validation of investment hypotheses.

The firm is particularly relevant in middle-market transactions where investors need practical, targeted, and evidence-based analysis without necessarily engaging a large strategy consultancy. Baker Tilly’s broader accounting, tax, transaction advisory, valuation, and advisory infrastructure can also support transaction processes beyond the commercial diligence workstream.

Baker Tilly is especially useful where clients require diligence that connects market evidence with financial, operational, tax, and transaction support. Its sector reach across manufacturing, distribution, technology, healthcare, business services, and other middle-market sectors gives it practical relevance in transactions where commercial and accounting-led diligence need to work together.

Baker Tilly belongs in Tier III because its commercial due diligence offering is explicit and active, but the firm is not primarily known as a specialist CDD strategy boutique. It is a useful extension candidate for middle-market diligence coverage.

Luminii Consulting

• Headquarters: London, United Kingdom
• Founded: 2017

Luminii Consulting is a specialist strategy and commercial due diligence advisory firm serving private equity investors, corporates, SMEs, and portfolio companies. The firm provides CDD, growth strategy, value creation, market intelligence, and strategic support to clients evaluating commercial opportunity and investment potential.

Its work is especially relevant for investors and management teams seeking focused diligence advice from a smaller, senior-led advisory platform. Luminii’s positioning around strategy, CDD, market research, and value creation makes it a cleaner fit than broader consulting firms with only indirect transaction exposure.

The firm is particularly useful in lower mid-market and growth-company settings where investors need direct access to experienced advisors, targeted market research, customer insight, and clear investment-relevant analysis. Its boutique structure can be valuable when deal teams require flexible support, sector learning, and rapid diligence execution.

Luminii belongs in Tier III because it is smaller than the established CDD platforms but active, focused, and directly aligned with this category. It should be treated as a specialist boutique rather than a Tier II anchor.

Matters GRAPH

• Headquarters: Washington, D.C., United States
• Founded: 2017 GRAPH Strategy lineage; current Matters Graph platform after GRAPH separation

Matters Graph is a specialist buy-side-focused consultancy providing commercial due diligence and commercial value-generation support for pre- and post-investment decisions. The firm continues the diligence-focused positioning associated with the GRAPH lineage, with emphasis on objective, evidence-based investment assessment.

Its relevance lies in its focus on buy-side decision support, market opportunity assessment, investment thesis testing, and commercial diligence best practices. Matters Graph is especially suitable for investors who need focused diligence support rather than broad general management consulting.

The firm is particularly relevant where investors require diligence that is hypothesis-driven, transaction-specific, and tied to the realities of ownership. Its work can support early-stage investment screening, deeper CDD, value creation planning, and post-investment commercial improvement.

Matters Graph belongs in Tier III because it is specialist and directly aligned with commercial due diligence, while still emerging as a distinct platform after the separation of the GRAPH-related businesses. It should be included carefully as a specialist extension rather than an established Tier II firm.

PMSI Strategy

• Headquarters: London, United Kingdom
• Founded: 1989

PMSI Strategy is a specialist strategy consultancy focused on commercial due diligence, market intelligence, strategy consulting, and performance improvement. The firm works with private equity investors, corporates, and management teams requiring evidence-based commercial assessment.

Its CDD work is relevant in transactions where market size, customer demand, competitive structure, pricing, growth prospects, and sector dynamics need to be evaluated quickly and independently. PMSI’s long operating history gives it credibility as a focused diligence and strategy boutique.

The firm is particularly useful in lower mid-market and specialist sector transactions where clients require targeted research, direct customer or market insight, and a practical view of growth potential. Its sector exposure includes business services, technology, healthcare, manufacturing, industrial markets, built environment, logistics, and related areas.

PMSI Strategy belongs in Tier III because it is active, specialist, and CDD-aligned, but less globally visible than the Tier II firms. It adds useful UK boutique coverage to the ranking and strengthens the specialist layer with a long-established commercial diligence platform.

---

Remarks

Commercial due diligence remains a central component of transaction decision-making, providing forward-looking insight into market dynamics, competitive positioning, and growth sustainability. As private equity and corporate investors continue to operate in increasingly competitive deal environments, the role of CDD advisors has become more critical in validating investment theses under compressed timelines.

Firms in this category are differentiated not only by analytical rigor but also by their ability to deliver clear, actionable insights that directly influence investment outcomes. Sector specialization, data-driven methodologies, and strong sponsor relationships continue to define leading positions within the market.

The composition of this ranking reflects a deliberate focus on advisory firms with established engagement in transaction-driven commercial analysis, distinct from broader strategy consulting or financial diligence services. This separation is intended to preserve clarity within the advisory taxonomy and ensure consistency across ranking categories.

Tier classification reflects relative institutional positioning within the commercial due diligence advisory segment and does not represent performance rankings or investment recommendations.

---

Recognition

Organizations included in the Top 20 Commercial Due Diligence (CDD) Advisory 2026 ranking may request information regarding authorized use of the Ranking News designation for marketing and communications purposes.

Recognized institutions may reference the designation in:

• corporate websites
• investor communications
• marketing materials
• client presentations

Ranking inclusion is editorially determined and independent of licensing, advertising, or commercial participation. Recognition-materials licenses govern only the use of official Ranking News / Advisory Ranking assets, approved wording, and related communications materials.

Licensing inquiries:
[email protected]